Compare IX & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IX | KVUE |
|---|---|---|
| Founded | 1950 | 2022 |
| Country | Japan | United States |
| Employees | 51921 | N/A |
| Industry | Diversified Financial Services | Specialty Chemicals |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1B | 34.9B |
| IPO Year | N/A | 2023 |
| Metric | IX | KVUE |
|---|---|---|
| Price | $30.01 | $17.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 424.7K | ★ 22.0M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | 2.60% | ★ 4.81% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $7.82 | $4.82 |
| Revenue Next Year | $5.97 | $2.61 |
| P/E Ratio | ★ $12.93 | $22.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.75 | $14.02 |
| 52 Week High | $37.04 | $25.17 |
| Indicator | IX | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 36.30 |
| Support Level | $29.41 | $17.20 |
| Resistance Level | $30.82 | $17.57 |
| Average True Range (ATR) | 0.55 | 0.30 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 52.43 | 30.84 |
ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.